BAVA Stock Overview
Develops, manufactures, and commercializes life-saving vaccines.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bavarian Nordic A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 267.70 |
| 52 Week High | DKK 300.00 |
| 52 Week Low | DKK 125.55 |
| Beta | 1.48 |
| 11 Month Change | 44.70% |
| 3 Month Change | 50.27% |
| 1 Year Change | 80.15% |
| 33 Year Change | -19.27% |
| 5 Year Change | 46.36% |
| Change since IPO | 4.98% |
Recent News & Updates
Recent updates
Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly
Aug 09
Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit
Jul 11Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts
May 12Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 09Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Feb 26Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry
Jan 03Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate
Dec 10Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly
Nov 15Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Aug 17Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 19Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?
Jan 03Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?
Sep 15Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic
Jul 24Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts
Jun 14Analyst Forecasts Just Became More Bearish On Bavarian Nordic A/S (CPH:BAVA)
May 31Is Bavarian Nordic (CPH:BAVA) Using Debt In A Risky Way?
May 06Shareholder Returns
| BAVA | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | 34.8% | 2.5% | -0.3% |
| 1Y | 80.1% | 3.9% | 25.4% |
Price Volatility
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 9.1% |
| 10% least volatile stocks in DK Market | 2.8% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,381 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
| BAVA fundamental statistics | |
|---|---|
| Market cap | DKK 20.83b |
| Earnings (TTM) | DKK 984.37m |
| Revenue (TTM) | DKK 6.64b |
21.2x
P/E Ratio3.1x
P/S RatioIs BAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAVA income statement (TTM) | |
|---|---|
| Revenue | DKK 6.64b |
| Cost of Revenue | DKK 2.04b |
| Gross Profit | DKK 4.60b |
| Other Expenses | DKK 3.62b |
| Earnings | DKK 984.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | 12.65 |
| Gross Margin | 69.29% |
| Net Profit Margin | 14.82% |
| Debt/Equity Ratio | 0.2% |
How did BAVA perform over the long term?
See historical performance and comparison